Aileron Therapeutics (ALRN) Key Ratios

$2.05

up-down-arrow $-0.06 (-2.84%)

As on 07-Feb-2025 09:30EDT

Market cap

info icon

$46 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -- -- -17.21 9.18 7.73
Net Profit 34.61 -220.03 -132.96 -7.18 -0.05
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-23Dec-22
EBIT-Margin info -----12,122.39----
Net Margin info --3,300.76-21,821.64----
Return on equity info -100.55-123.56-41.31-123.34-86.40
Return on Capital info -100.03-110.99---122.95-86.13
Return on Assets info -60.24-76.80-47.04-24.58-76.64
Debt to Equity (x) info ----0.000.010.00
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
--
-122.95
-86.13
-91.01
-129.76
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-41.31

Lower than Peers by 0.91

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-41.31
-123.34
-86.40
-91.91
-154.68
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-47.04

Lower than Peers by 16.06

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-47.04
-24.58
-76.64
-79.49
-101.92
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-12,122.39

Lower than Peers by 12,038.77

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-12,122.39
--
--
--
--
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-21,821.64

Lower than Peers by 21,728.97

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-21,821.64
--
--
--
3,300.76
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-0.19

Lower than Peers by 0.19

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-0.19
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-17.21

Lower than Peers by 16.41

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-17.21
43.10
-3.92
-29.81
31.58
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-132.96

Lower than Peers by 125.66

Year on year growth in profit after tax

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-132.96
41.76
-4.84
-18.09
24.20
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
--
0.01
0.00
0.00
0.03
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
--
0.01
0.00
0.00
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.30

Lower than Peers by 2.51

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
3.30
4.17
6.46
10.69
4.12
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.30

Lower than Peers by 2.39

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
3.30
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-13.28

Lower than Peers by 11.19

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-13.28
--
-86.94
-66.51
--
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
--
--
--
--
--
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.00

Lower than Peers by 0.06

Sales / Average Total Assets

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
0.00
--
--
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
--
4,465.87
3,166.22
4,235.09
3,414.98
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.88

Lower than Peers by 4.30

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
0.88
--
--
--
--
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-0.64

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
-0.64
1.11
0.77
1.73
0.66
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

46

Lower than Peers by 100

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Aileron Therapeutics (ALRN)
46
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...